Evidence map›Paper›PMID 25819469›Full record

ArticleUltrasound in medicine & biology2015

Nitric Oxide-Enhanced Molecular Imaging of Atheroma using Vascular Cellular Adhesion Molecule 1-Targeted Echogenic Immunoliposomes.

Hyunggun Kim, Patrick H Kee, Yonghoon Rim, Melanie R Moody, Melvin E Klegerman, Deborah Vela, Shao-Ling Huang, David D McPherson, Susan T Laing

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ultrasound in medicine & biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Targeting therapeutics to endothelium: are we there yet?Drug delivery and translational research · 2018
    Review
  3. Biomimetic nanoparticles for inflammation targeting.Acta pharmaceutica Sinica. B · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hyunggun KimDivision of Cardiology, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Patrick H KeeDivision of Cardiology, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Yonghoon RimDivision of Cardiology, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Melanie R MoodyDivision of Cardiology, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Melvin E KlegermanDivision of Cardiology, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Deborah VelaDepartment of Pathology, Texas Heart Institute, Houston, Texas, USA.
Shao-Ling HuangDivision of Cardiology, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
David D McPhersonDivision of Cardiology, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Susan T LaingDivision of Cardiology, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA. Electronic address: Susan.T.Laing@uth.tmc.edu.

Funding

Center for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4M
Echogenic Targeted Liposomes:Transfection/Drug DeliveryR01HL074002 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2004 to 2013
$5.3M
TARGETED LIPOSOMES FOR ACOUSTIC CARDIOVASCULAR IMAGINGR01HL059586 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 1998 to 2012
$3.2M
NCATS NIH HHS UL1 TR000371NHLBI NIH HHS HL059786NHLBI NIH HHS HL74002NHLBI NIH HHS R01 HL059586NHLBI NIH HHS R01 HL074002
6 · The paper itself

Abstract

The aim of this study was to determine whether pre-treatment with nitric oxide-loaded echogenic liposomes (NO-ELIP) plus ultrasound can improve highlighting by molecularly targeted (anti-vascular cell adhesion molecule 1 [VCAM-1]) ELIP of atheroma components. Atherosclerotic animals were treated with anti-VCAM-1-ELIP or immunoglobulin (IgG)-ELIP. Each group was selected at random to receive pre-treatment with standard ELIP plus ultrasound, NO-ELIP without ultrasound and NO-ELIP plus ultrasound. Intravascular ultrasound highlighting data for the same arterial segments were collected before and after treatment. Pre-treatment with NO-ELIP plus ultrasound resulted in a significant increase in acoustic enhancement by anti-VCAM-1-ELIP (21.3 ± 1.5% for gray-scale value, 53.9 ± 3.1% for radiofrequency data; p < 0.001 vs. IgG-ELIP, p < 0.05 vs. pre-treatment with standard ELIP plus ultrasound or NO-ELIP without ultrasound). NO-ELIP plus ultrasound can improve highlighting of atheroma by anti-VCAM-1 ELIP. This NO pre-treatment strategy may be useful in optimizing contrast agent delivery to the vascular wall for both diagnostic and therapeutic applications.

Indexed as

AnimalsDisease Models, AnimalLiposomesMolecular ImagingNitric OxidePlaque, AtheroscleroticSwineSwine, MiniatureUltrasonographyVascular Cell Adhesion Molecule-1LiposomesNitric OxideVascular Cell Adhesion Molecule-1AtheromaContrast agentContrast echocardiographyEarly atherosclerosisMolecular imagingNitric oxideUltrasoundVascular cell adhesion molecule

Identifiers

PMID25819469
PMCPMC4426087

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.